Polar Asset Management Partners Inc. Travere Therapeutics, Inc. Transaction History

Polar Asset Management Partners Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$15.3 - $22.61 $8.68 Million - $12.8 Million	-567,225 Reduced 71.06%	230,965 $3.55 Million
Q1 2023 May 15, 2023	BUY	$17.82 - $22.89 $8.57 Million - $11 Million	480,900 Added 151.56%	798,190 $18 Million
Q4 2022 Feb 14, 2023	SELL	$18.47 - $26.14 $461,750 - $653,500	-25,000 Reduced 7.3%	317,290 $6.67 Million
Q3 2022 Nov 14, 2022	SELL	$22.91 - $28.63 $5.51 Million - $6.88 Million	-240,410 Reduced 41.26%	342,290 $8.43 Million
Q2 2022 Aug 15, 2022	BUY	$20.94 - $30.01 $10.3 Million - $14.7 Million	491,500 Added 538.93%	582,700 $14.1 Million
Q1 2022 May 16, 2022	BUY	$23.61 - $30.6 $2.15 Million - $2.79 Million	91,200 New	91,200 $2.35 Million
Q4 2021 Feb 14, 2022	SELL	$24.34 - $31.17 $6.27 Million - $8.03 Million	-257,500 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$12.98 - $25.03 $3.34 Million - $6.45 Million	257,500 New	257,500 $6.24 Million

199

85.2M

776K

912K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.35B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Polar Asset Management Partners Inc., based on Form 13F filings with the SEC.

Stay updated on Polar Asset Management Partners Inc. with notifications on news.